AbbVie

Dr toon van gorp: Mirvetuximab soravtansine should be global standard for FRα+ ovarian cancer American Journal of Managed Care13:18Ovarian Cancer Cancer Pharma

AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer Clinical Trials Arena10:54Ovarian Cancer Cancer Pharma

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial PMLiVE12:31Ovarian Cancer Cancer Treatment Cancer

AbbVie's Elahere cuts death risk by 32%, shows consistent survival benefit in long-term analysis for certain ovarian… Benzinga18:25Ovarian Cancer Cancer Treatment Cancer

AbbVie (NYSE:ABBV) reports Elahere success in phase 3 trials for platinum-resistant ovarian cancer Simply Wall St21:40FDA Stock Markets (World) Stock Market (US)

American pharmaceutical companies still aren’t paying tax in the U.S. Council on Foreign Relations17:20Eli Lilly Pfizer Bristol Myers Squibb

FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on drug manufacturing; AbbVie’s move into the… ENDPOINTS11:10FDA Pharma Tariffs

AbbVie enters obesity treatment via Gubra licensing agreement Yahoo! UK & Ireland21:03Biotech Pharma

AbbVie, reddit, allegro microsystems: Market minute Yahoo! UK & Ireland18:21Biotech Pharma

AbbVie joins obesity treatment market with up to $2.2B Licensing deal Yahoo! US19:31Novo Nordisk Pharma Biotechnology

Genmab refutes Trade Secret claims in complaint by AbbVie Bloomberg Law04:34Biotech Biotechnology Pharma

AbbVie (NYSE:ABBV) urges shareholders to reject proposals on voting rules and human rights due diligence Simply Wall St20:46Stock Markets (World) Stock Market (US) Civil Liberties & Rights

Big pharma fears best-selling Irish drugs in crosshairs of Trump tariffs BreakingNews.ie13:51Merck and Co Cancer Treatment Pharma

Latest News

In the last 4 hours

Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims TipRanks12:51

In the last 7 days

Nvidia, Exxon, AbbVie, Uber, Adobe: Insider Moves Unveiled TipRanks13:01 22-Mar-25

Genmab Refutes Trade Secret Claims in Complaint by AbbVie Bloomberg Law04:34 22-Mar-25

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. GlobeNewswire (Press Release)03:29 22-Mar-25

Aquipta hailed as game-changer in migraine prevention at AbbVie symposium Korea Biomedical Review05:55 21-Mar-25

Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends The Motley Fool13:32 20-Mar-25

Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer American Journal of Managed Care13:18 20-Mar-25

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial PMLiVE12:31 19-Mar-25

Big pharma fears best-selling Irish drugs in crosshairs of Trump tariffs BreakingNews.ie13:51 18-Mar-25

Updated MIRASOL Data Confirms Efficacy of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer American Journal of Managed Care18:39 17-Mar-25

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian… Benzinga18:25 17-Mar-25

AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer Clinical Trials Arena10:54 17-Mar-25

The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands Zacks09:34 17-Mar-25

In the last month

AbbVie (NYSE:ABBV) Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer Simply Wall St21:40 16-Mar-25

AbbVie builds the case for ovarian cancer drug Elahere pharmaphorum20:05 16-Mar-25

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian… AbbVie (Press Release)12:05 15-Mar-25

American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S. Council on Foreign Relations17:20 14-Mar-25

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk Seeking Alpha20:05 13-Mar-25

AbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on top FiercePharma16:12 12-Mar-25

AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence Simply Wall St20:46 11-Mar-25

As Humira succession plan played out, AbbVie's Rob Michael collected $18.5M in his first year… FiercePharma17:28 11-Mar-25

With AbbVie in its sights, Tenpoint names commercial chief ahead of vision drug launch FiercePharma17:07 11-Mar-25

Zacks Market Edge Highlights: Berkshire Hathaway, Aon plc and AbbVie Zacks15:06 10-Mar-25

Pfizer, Walmart, Super Micro, Salesforce, AbbVie: Insider Moves Unveiled TipRanks13:09 8-Mar-25

FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on drug manufacturing; AbbVie’s move into the… ENDPOINTS11:10 8-Mar-25

AbbVie and Besins Healthcare Settle Oregon Antitrust Allegations Over Testosterone Drug JD Supra13:49 7-Mar-25

Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch… GlobeNewswire (Press Release)12:29 7-Mar-25

No Cancer Therapy Patent For AbbVie, Says Federal Circuit Law36022:34 6-Mar-25

AbbVie Steps Into The Ring In The Obesity Drug Wars Seeking Alpha16:45 6-Mar-25

Here's How to Play AbbVie Stock as it Enters the Obesity Space Zacks13:10 5-Mar-25

AbbVie to Present at the Leerink Partners Global Healthcare Conference AbbVie (Press Release)13:03 4-Mar-25

AbbVie Buys Into Obesity With Gubra Deal, While Novo Partners With Gensaic Scrip Pharma Intelligence23:54 3-Mar-25

Abbvie enters $2.2B deal for Gubra’s amylin obesity drug BioWorld21:22 3-Mar-25

AbbVie enters obesity treatment via Gubra licensing agreement Yahoo! UK & Ireland21:03 3-Mar-25

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal Yahoo! US19:31 3-Mar-25

AbbVie, Reddit, Allegro MicroSystems: Market Minute Yahoo! UK & Ireland18:21 3-Mar-25

AbbVie Enters Obesity Market With Up to $2.2 Billion Gubra Deal Bloomberg Law12:32 3-Mar-25

AbbVie enters obesity space with $2.3bn Gubra deal Pharmaceutical Technology12:13 3-Mar-25

AbbVie pays Gubra $350M to make late play for obesity space FierceBiotech10:35 3-Mar-25

AbbVie pays Gubra $350m upfront to enter obesity field pharmaphorum10:00 3-Mar-25

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin ENDPOINTS08:57 3-Mar-25

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of… PR Newswire (Press Release)06:14 3-Mar-25

CHMP recommends AbbVie’s Rinvoq be approved for adult GCA Pharmaceutical Technology15:35 28-Feb-25

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? Barchart14:45 28-Feb-25

AbbVie closes on Rinvoq approval in inflamed artery disease pharmaphorum13:00 28-Feb-25

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis AbbVie (Press Release)07:07 28-Feb-25

AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference AbbVie (Press Release)13:01 26-Feb-25

The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic Barchart10:28 24-Feb-25

Why AbbVie Remains A Strong Buy For Long-Term Investors Seeking Alpha17:47 23-Feb-25

See Which Of The Latest 13F Filers Holds ABBV Nasdaq17:40 21-Feb-25

view more headlines

24 Mar 12:51

AbbVie News

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.